ALC
HealthcareAlcon Inc. · Medical - Instruments & Supplies · $33B
What is Alcon Inc.?
Alcon Inc. is a global eye care company headquartered in Geneva, Switzerland, serving eye care professionals and patients across more than 140 countries. Its product portfolio spans surgical equipment and vision care consumables.
Alcon operates through two segments: Surgical and Vision Care. The Surgical segment provides equipment, intraocular lenses, and consumables used in cataract, vitreoretinal, and refractive procedures. The Vision Care segment offers contact lenses — daily disposable, reusable, and color-enhancing — alongside ocular health products targeting dry eye and glaucoma management. Revenue is generated through direct sales to hospitals, surgical centers, eye care clinics, and retail channels worldwide.
Alcon became an independent publicly traded company in 2019, though its roots in eye care stretch back decades.
- Cataract surgery systems including femtosecond laser and visualization platforms
- Advanced intraocular lenses under the PanOptix and ReSTOR brands
- Vitreoretinal surgical instruments and procedure packs
- Daily disposable and reusable contact lenses
- Dry eye and ocular health consumer products
Is ALC a Good Stock to Buy?
UQS Score rates ALC as Below Average overall, reflecting a mixed picture across its five quality pillars.
Alcon's Valuation pillar stands out as the relative bright spot, rated Good — suggesting the market may not be pricing in excessive optimism. The Moat, Growth, and Risk pillars each land at Neutral, indicating a company that holds a defensible position in eye care without delivering standout fundamental momentum.
The Quality pillar is rated Weak, which is the primary drag on the composite score and signals that underlying financial returns have room to improve relative to sector peers.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ALC pay dividends?
Yes — Alcon Inc. pays a dividend.
Alcon pays a regular dividend, which is relatively uncommon among large-cap medical device companies still investing heavily in R&D and global expansion. The dividend reflects a degree of financial stability, though the payout is modest relative to the broader healthcare sector. Income-focused investors should weigh the dividend alongside the company's ongoing capital allocation priorities.
When does ALC report earnings?
Alcon reports earnings on a quarterly cadence, consistent with standard practice for US-listed large-cap equities.
Alcon's recent results have reflected steady demand across both its Surgical and Vision Care segments, with growth driven by global cataract procedure volumes and contact lens adoption. Performance has been tempered by currency headwinds and ongoing investment in product innovation.
For the most recent quarter's results and guidance, visit Alcon's official investor relations page.
ALC Price History
+13.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Alcon Inc.?
Based on Alcon Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ALC Long-term Outlook
Alcon's fundamental outlook is shaped by Neutral Growth and Neutral Risk pillar ratings, pointing to a company on a measured trajectory rather than a high-acceleration path. The aging global population and rising demand for cataract and refractive procedures provide a structural tailwind, while the Vision Care segment benefits from growing contact lens penetration in emerging markets. However, the Weak Quality pillar suggests that translating top-line growth into strong financial returns remains a work in progress.
Growth drivers
- Aging global demographics driving higher cataract surgery volumes
- Expanding contact lens adoption in emerging and developing markets
- Innovation in premium intraocular lens technology and surgical platforms
Key risks
- Persistent currency headwinds given broad international revenue exposure
- Competitive pricing pressure in the contact lens and surgical consumables markets
- Execution risk on margin improvement given the current Weak Quality rating
ALC vs Peers
Alcon competes across the broader medical device and healthcare products landscape, where several large-cap peers offer overlapping or adjacent product categories.
Medline focuses on a broad range of medical supplies and distribution rather than the specialized ophthalmic niche that defines Alcon's core business.
ResMed concentrates on respiratory care and sleep-disordered breathing solutions, competing with Alcon for healthcare capital allocation rather than direct product overlap.
Becton Dickinson operates across a much wider medical technology portfolio, giving it scale advantages but less focus on the eye care specialization that anchors Alcon's strategy.
Frequently Asked Questions
What does Alcon do?
Alcon is a global eye care company that develops, manufactures, and sells products for eye care professionals and patients. Its two main segments are Surgical — covering cataract, vitreoretinal, and refractive surgery equipment — and Vision Care, which includes contact lenses and ocular health products such as dry eye treatments.
Does ALC pay dividends?
Yes, Alcon pays a regular dividend. The payout is modest relative to many healthcare peers, reflecting the company's ongoing investment in R&D and global market expansion. Investors seeking income should review the current dividend details on Alcon's investor relations page for the most up-to-date figures.
When does ALC report earnings?
Alcon reports earnings on a quarterly cadence, as is standard for large-cap US-listed companies. The company typically provides revenue and segment-level updates alongside guidance. For the exact schedule of upcoming releases, check Alcon's investor relations page directly.
Is ALC a good stock to buy?
The UQS Score rates ALC as Below Average overall. The Valuation pillar is rated Good, and Moat, Growth, and Risk are each Neutral — but the Weak Quality pillar weighs on the composite. Whether ALC fits a portfolio depends on individual goals and risk tolerance. The full pillar breakdown is available to UQS Pro members.
Is ALC overvalued?
The UQS Valuation pillar for ALC is rated Good, suggesting the stock is not trading at an extreme premium relative to its fundamentals. That said, valuation is one of five pillars — the Weak Quality rating means investors should consider whether the price reflects the company's current return profile.
How does ALC compare to its competitors?
Alcon's focus on ophthalmic surgery and vision care gives it a more specialized profile than broad medical device peers like Becton Dickinson. Competitors such as ResMed and Medline operate in different healthcare subsectors, making direct comparison less about product overlap and more about capital allocation within the healthcare space.
What is ALC's market cap bracket?
Alcon is classified as a large-cap company, placing it among the more established and widely followed names in the global healthcare sector. Large-cap status generally implies greater liquidity and institutional coverage compared to smaller peers.
Who founded Alcon?
Alcon's origins trace back to a small pharmacy in Fort Worth, Texas, founded in 1945. The company grew into a global eye care leader over decades before being spun off as an independent publicly traded entity in 2019. Founding history is widely documented in public sources.
Is ALC a long-term quality investment?
From a long-term quality perspective, ALC's Neutral Moat rating suggests some degree of competitive durability in the specialized eye care market. However, the Weak Quality pillar indicates that financial returns have not yet reached levels associated with the strongest long-term compounders. The UQS framework helps frame this trade-off clearly.
What is the main competitive advantage of Alcon?
Alcon's competitive position rests on its specialized focus in eye care, a broad portfolio spanning both surgical and consumer vision products, and long-standing relationships with eye care professionals globally. Its branded intraocular lens platforms and surgical systems create switching costs within hospital and clinic settings.
What sector does ALC belong to?
Alcon operates in the Healthcare sector, specifically within the medical devices and equipment subsegment. Its dual focus on surgical technology and consumer vision care products gives it exposure to both professional healthcare spending and direct-to-consumer optical markets.
Is ALC a growth stock or value stock?
Based on UQS pillar labels, ALC sits in a middle ground. The Growth pillar is rated Neutral — neither a high-growth accelerator nor a stagnant business — while the Valuation pillar is rated Good, suggesting it is not priced as a premium growth stock. It may appeal to investors seeking moderate growth at a reasonable valuation.
Unlock Full ALC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare ALC against sector peers on quality factors
- ✓See the complete Valuation and Risk breakdown
- ✓Get the full analyst-style report for Pro members
Pro Analysis
ALC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 46.3 | 36.4 | 42.0 | 39.1 | 60.9 | 64.7 | -0.2 |
| May 22, 2026 | 46.5 | 36.4 | 42.0 | 39.4 | 60.9 | 65.9 | -0.3 |
| May 21, 2026 | 46.8 | 36.7 | 42.0 | 39.5 | 60.9 | 67.2 | 0.0 |
| May 20, 2026 | 46.8 | 36.7 | 42.0 | 39.5 | 60.9 | 67.6 | -0.1 |
| May 19, 2026 | 46.9 | 37.1 | 42.0 | 39.5 | 60.9 | 67.4 | -0.2 |
| May 17, 2026 | 47.1 | 37.1 | 42.0 | 39.5 | 60.9 | 68.4 | -0.1 |
| May 16, 2026 | 47.2 | 37.1 | 42.0 | 39.5 | 60.9 | 69.5 | -0.4 |
| May 15, 2026 | 47.6 | 37.2 | 42.0 | 39.8 | 60.9 | 71.1 | 0.0 |
| May 14, 2026 | 47.6 | 37.2 | 42.0 | 39.8 | 60.9 | 71.4 | -0.6 |
| May 13, 2026 | 48.2 | 37.4 | 42.0 | 40.6 | 60.9 | 73.7 | -0.1 |
ALC — Pillar Breakdown
Quality
— 36.4/100 (25%)Alcon Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 39.1/100 (20%)Alcon Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 60.9/100 (15%)Alcon Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 66.7/100 (15%)Alcon Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Alcon Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ALC.
Score Composition
Financial Data
More Stock Analysis
How is the ALC UQS Score Calculated?
The UQS (Unified Quality Score) for Alcon Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Alcon Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Alcon Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.